Disease · MONDO_0009807
Comparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 20
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Osteosarcoma vs Ewing Sarcoma: Incidence of Adverse Events | 45 of 45 | 45 of 45 | 90 | NCT02243605 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: deaths from any cause | 42 of 45 | 37 of 45 | 90 | NCT02243605 | Trial comparisons |
| Osteosarcoma vs Ewing Sarcoma: serious adverse events | 30 of 45 | 31 of 45 | 90 | NCT02243605 | Trial comparisons |
| Cohort 1: Measurable vs Cohort 2: Resection: deaths from any cause | 13 of 15 | 20 of 38 | 53 | NCT02470091 | Trial comparisons |
| Cohort 1: Measurable vs Cohort 2: Resection: serious adverse events | 6 of 15 | 4 of 38 | 53 | NCT02470091 | Trial comparisons |
| Group 1 (Unilateral Recurrence) vs Group 2 (Bilateral Recurrence): serious adverse events | 4 of 27 | 0 of 16 | 43 | NCT00066365 | Trial comparisons |
| A: Localized Resectable Disease vs C: Metastatic Tumors: serious adverse events | 3 of 31 | 0 of 11 | 42 | NCT00667342 | Trial comparisons |
| Cohort A: Liposarcoma Crossover vs Cohort B: Osteosarcoma Crossover: Response Rate (RR), Cohorts A and B, After Crossover. | 0 of 15 | 0 of 11 | 26 | NCT02048371 | Trial comparisons |
| Cisplatin Liposomal 24 mg/m2 vs Cisplatin Liposomal 36 mg/m2: deaths from any cause | 0 of 7 | 0 of 12 | 19 | NCT00102531 | Trial comparisons |
| Cisplatin Liposomal 24 mg/m2 vs Cisplatin Liposomal 36 mg/m2: serious adverse events | 1 of 7 | 2 of 12 | 19 | NCT00102531 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | 1 of 10 | 0 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Laboratory Abnormalities | 0 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Physical Examination Abnormalities | 6 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: deaths from any cause | 6 of 10 | 2 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Vital Signs Abnormalities | 0 of 10 | 0 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: serious adverse events | 7 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Part A: 20 mg/kg (Phase 1) vs Part A PK: 20 mg/kg (Expansion): Disease Control Rate (Part A) | 0 of 6 | 0 of 6 | 12 | NCT03320330 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Dose-Limiting Toxicities (DLT) | 0 of 8 | 2 of 3 | 11 | NCT05093322 | Trial comparisons |
Dose Escalation Part With Sirolimus (Si) Dose 4 mg vs Dose Escalation Part With Sirolimus (SI) Dose 6 mg: Dose Escalation Part : Antitumor Activity Observed With Sirolimus Combined With CP, MT and ZA, 1-year Progression-free Survival (PFS) | 6 of 6 | 1 of 3 | 9 | NCT02517918 | Trial comparisons |
Dose Escalation Part With Sirolimus (Si) Dose 4 mg vs Dose Escalation Part With Sirolimus (SI) Dose 6 mg: Dose Escalation Part : Antitumor Activity Observed With Sirolimus Combined With CP, MT and ZA, 1-year Overall Survival (OS) | 3 of 6 | 0 of 3 | 9 | NCT02517918 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009807/comparisons